Stock Track | Royalty Pharma Plunges 6.31% in Pre-Market After Q4 Sales Miss Estimates

Stock Track

Yesterday

Royalty Pharma plc (NASDAQ: RPRX) experienced a pre-market plunge of 6.31% on Wednesday following the release of its fourth-quarter and full-year 2025 results.

The company reported quarterly adjusted earnings per share of $1.47, beating analyst estimates of $1.33. However, quarterly sales came in at $622 million, significantly missing the consensus estimate of $795.915 million by approximately 21.85%. This substantial revenue shortfall appears to be the primary driver behind the stock's sharp decline in pre-market trading.

While other metrics such as adjusted EBITDA of $816 million exceeded expectations, the sales miss overshadowed these positive aspects, leading to negative investor sentiment ahead of the market open.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1174108795"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174108795\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174108795?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-11 22:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174108795","market":"nz","top_or_hot":-1,"title":"Stock Track | Royalty Pharma Plunges 6.31% in Pre-Market After Q4 Sales Miss Estimates","media":"Stock Track","content":"<p>Royalty Pharma plc (NASDAQ: RPRX) experienced a pre-market plunge of 6.31% on Wednesday following the release of its fourth-quarter and full-year 2025 results.</p><p>The company reported quarterly adjusted earnings per share of $1.47, beating analyst estimates of $1.33. However, quarterly sales came in at $622 million, significantly missing the consensus estimate of $795.915 million by approximately 21.85%. This substantial revenue shortfall appears to be the primary driver behind the stock's sharp decline in pre-market trading.</p><p>While other metrics such as adjusted EBITDA of $816 million exceeded expectations, the sales miss overshadowed these positive aspects, leading to negative investor sentiment ahead of the market open.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Royalty Pharma Plunges 6.31% in Pre-Market After Q4 Sales Miss Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Royalty Pharma Plunges 6.31% in Pre-Market After Q4 Sales Miss Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-11 22:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Royalty Pharma plc (NASDAQ: RPRX) experienced a pre-market plunge of 6.31% on Wednesday following the release of its fourth-quarter and full-year 2025 results.</p><p>The company reported quarterly adjusted earnings per share of $1.47, beating analyst estimates of $1.33. However, quarterly sales came in at $622 million, significantly missing the consensus estimate of $795.915 million by approximately 21.85%. This substantial revenue shortfall appears to be the primary driver behind the stock's sharp decline in pre-market trading.</p><p>While other metrics such as adjusted EBITDA of $816 million exceeded expectations, the sales miss overshadowed these positive aspects, leading to negative investor sentiment ahead of the market open.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RPRX","symbol_name":"Royalty Pharma plc","start_time":0,"source_url":"","article_id":"1174108795","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174108795","pubTimestamp":1770820121,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Royalty Pharma plc (NASDAQ: RPRX) experienced a pre-market plunge of 6.31% on Wednesday following the release of its fourth-quarter and full-year 2025 results.The company reported quarterly adjusted...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RPRX":"Royalty Pharma plc"},"translate_title":"个股追踪|Royalty Pharma盘前暴跌6.31%因第四季度销售未达预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RPRX":1},"content_text":"Royalty Pharma plc (NASDAQ: RPRX) experienced a pre-market plunge of 6.31% on Wednesday following the release of its fourth-quarter and full-year 2025 results.The company reported quarterly adjusted earnings per share of $1.47, beating analyst estimates of $1.33. However, quarterly sales came in at $622 million, significantly missing the consensus estimate of $795.915 million by approximately 21.85%. This substantial revenue shortfall appears to be the primary driver behind the stock's sharp decline in pre-market trading.While other metrics such as adjusted EBITDA of $816 million exceeded expectations, the sales miss overshadowed these positive aspects, leading to negative investor sentiment ahead of the market open.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}